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Abstract 
 
In a randomized trial of folic acid supplementation for the prevention of colorectal 
adenomas, we previously found indications of increased risk during later treatment and 
follow-up. This could have been due to the unmetabolized folic acid or the natural reduced 
and methylated folates to which it is metabolized.  In post hoc analyses, we measured 
methylated folates (mF, the sum of 5-methyl-tetrahydrofolate and 4-alfa-hydroxy-5-
methyl-THF) and unmetabolized folic acid (UFA) concentrations in the serum of 924 
participants. Using binomial regression models with a log link, we assessed the associations 
between plasma mF or UFA and adenoma occurrence. We found no association between 
plasma mF or UFA and overall adenoma risk.  However, during later follow-up, the pre-
specified, composite endpoint of high risk findings (advanced or multiple adenomas) was 
positively associated with plasma mF (Plinear trend=0.009), with a 58% increased risk for 
participants in the upper versus lowest quartile. An irregular association was seen with 
plasma UFA, with suggestions of an inverse trend (Plinear trend=0.049). A modest, significant 
inverse association was also seen between mF and risk of serrated lesions, with a 39% 
lower risk for upper vs lower quartile participants (Plinear trend=0.03). In conclusion, during 
the later follow-up period in which folic acid supplementation was previously seen to 
increase the risk of advanced and multiple adenomas, higher serum mF was associated 
with a higher risk of multiple and/or advanced adenomas, but no clear indication that UFA 
played a direct role. There were indications that higher mF was associated with reduced 
risk of serrated polyps. 
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Introduction 
Extensive epidemiological and preclinical data have suggested that folates, a family of 
water-soluble vitamins that serve as cofactors for DNA synthesis and methylation 
reactions, exert substantial anti-neoplastic effects (1). Motivated by these findings, we 
conducted a randomized controlled trial to test the effect of 1g/day folic acid for the 
prevention of colorectal adenoma recurrence (2).  Although we found no effect during the 
first three years of treatment, we saw unexpected indications of increased risk during 
subsequent follow-up and treatment:  the relative risk for the occurrence of advanced 
adenomas was 1.67 (95% CI 1.00-2.80) and for 3 or more adenomas, 2.32 (95% CI 1.23-
4.35) (2).    
Although our finding of increased adenoma risk from folic acid supplementation 
may have been due to chance, there are other indications of increased cancer-related risks 
of folic acid, depending on dose, timing and folate status before supplementation. Whereas 
moderate doses may reduce risk, carcinogenesis may be enhanced by larger doses, or by 
supplementation after a neoplastic lesion has developed (3-6). The mechanisms for this 
adverse effect have not been fully elucidated but may include the provision of nucleotides 
for carcinogenesis (7). 
Folic acid, is a stable, oxidized molecule rarely found in nature, though widely used 
for food fortification and in supplements.  Folic acid is the molecular backbone of folates, 
but it is inactive until it is metabolized into the natural reduced forms, including 5-
methyltetrahydrofolate (5m-THF), the prevailing circulating folate species (8).   Since folic 
acid enters the folate metabolic cycles differently than 5m-THF and has a distinct 
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metabolism, it may have biological effects that differ from those of the naturally occurring 
folates.  For example, some studies suggest that UFA reduces natural killer cell cytotoxicity 
in vitro (9, 10). Thus the increased risks associated with folic acid supplementation in our 
study could have been the result of folic acid itself, not the 5m-THF generated by it.    
For both 5m-THF and folic acid, genetic variants in folate metabolism may also be 
pertinent. For example, the homozygous C677T variant of methylenetetrahydrofolate 
reductase (MTHFR), which metabolizes methylenetetrahydrofolate to mTHF, may modify 
the association of folate status with risk of  colorectal carcinoma and adenoma (11-13). 
MTRR, methionine synthase reductase, maintains methionine synthase in its active form, 
and in this state maintains intracellular folate levels (14). 
It is widely recognized that colorectal cancer is a heterogenous disease, with two 
distinct precursor pathways: the conventional pathway (accounting for about 60% of 
colorectal cancers), and the serrated pathway, which leads to CpG island methylated 
colorectal cancers (accounting for the remaining ~40%) (15, 16).  Since these involve 
distinct genetic and epigenetic processes, it is possible that folates affect  these pathways in 
different ways.  
In a secondary, observational analysis, we previously found no consistent 
association between folate status and adenoma risk (17). However, during early follow-up, 
total folate intake and plasma total folate were inversely associated with adenoma risk 
among subjects randomized to folic acid placebo, while in later follow-up there were 
inconsistent suggestions of increased risks for dietary folate intake and red blood cell 
folate. In this analysis, we extend our analyses using separate measures of plasma UFA and 
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methylated folate (mF), and separate assessment of the conventional adenoma pathway 
and the serrated pathway. We hypothesized that long-term risk after folic acid 
supplementation is independently associated with plasma UFA levels.  
 
Methods 
Briefly, we conducted a double-blinded, placebo-controlled, randomized trial 
(NCT00272324) in a 3 x 2 factorial design to compare the effects of oral aspirin (81mg/day, 
325 mg/day or placebo) with placebo or folic acid 1 g/day, in the prevention of colorectal 
adenomas in persons with a history of adenomas (2, 18).  The trial’s primary outcome was 
the occurrence of ≥1 colorectal adenomas. Secondary outcomes were the occurrence of 
advanced adenomas (tubulovillous or villous adenomas, or adenomas that were large 
(≥1cm) or had invasive cancer or high grade dysplasia); high risk findings (≥1 advanced 
adenomas or ≥3 adenomas); and serrated lesions (comprising hyperplastic polyps, sessile 
serrated adenomas/polyps, and traditional serrated adenomas). The recruitment period 
(1994-98) coincided with the beginning of folic acid food fortification in the U.S. and 
Canada that became mandatory in 1998 (19, 20).  All participants provided written 
informed consent; the trial was approved by each participating center’s institutional 
review board.  
 Participants aged 21-80 with a recent adenoma and no known remaining adenomas 
after a complete colonoscopy were identified at nine clinical centers, as described 
previously (18). Exclusion criteria included vitamin B12 deficiency, contraindication to 
aspirin treatment, or ongoing treatment with aspirin or related compounds (2, 18). 
 After a run-in phase of approximately 3 months, 1021 participants were randomized 
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to aspirin (81 mg, 325 mg or placebo) and folic acid (1 mg or placebo); 100 early 
participants were randomized only to aspirin/placebo. The initially planned study 
interventions continued until a follow-up colonoscopy anticipated approximately 3 years 
after the qualifying examination.  This demarcated the end of the first follow-up interval 
and the beginning of the second interval, which lasted until 6 years later, one year longer 
than a 5-year colonoscopic surveillance cycle (Figure 1).  
 At the end of the first follow-up interval, participants were asked to continue 
placebo/folic acid treatment until their next surveillance colonoscopy, anticipated 3 to 5 
years later; 729/1084 (67%) agreed to do so (Figure 1). Of the 355 who chose to 
discontinue randomized treatment, 278 (78%) agreed to observational follow-up.   
Participants still on study treatment were asked to stop taking study tablets by October 1, 
2004 because folic acid supplementation had been associated with increased adenoma risk.  
 
Plasma measures  
Blood samples were collected at enrollment (“year 0”, reflecting pre-randomization folate 
status), and shortly before the end of the first treatment interval (“year 3”), reflecting folate 
status on treatment. The blood draws were not timed to intake of food or study tablets. 
This study examined associations with circulating concentrations of folic acid and 
naturally-occurring folates shortly before the year 3 colonoscopy.  
 Plasma levels of 5m-THF, 4-α-hydroxy 5-methyl-THF (hm-THF), and unmetabolized 
folic acid (UFA) were analyzed at Bevital (21), using LC MS/MS (22). hm-THF is formed 
upon degradation of 5m-THF during storage so we pooled these measures for each sample 
and refer to the sum as methylated folate (mF) (22). The levels of detection were 0.27 
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nmol/L for UFA, 0.20 nmol/L for hm-THF and 0.07 nmol/L for 5m-THF (22). The intra-run 
CVs ranged from 5.0% to 9.9%, and the inter-run CVs from 3.3% to 9.5% (22). We 
identified the 677C>T, V222A (rs1801133) polymorphism of the 
methylenetetrahydrofolate reductase (MTHFR) gene and the 66A>G, I22M (rs1801394) 
polymorphism of methionine synthase reductase (MTRR) as previously described (23).  
 
Follow-up 
Participants taking study treatments were contacted every 4 months for information on 
adherence, use of personal nutritional supplements including folic acid, large bowel 
endoscopies and major medical events. During observational follow-up, they were 
contacted annually. For all tissue removed from the bowel, slides were obtained if possible 
and sent to a single, blinded pathologist for classification.  
 
Statistical Analysis  
We used conventional descriptive statistics to summarize characteristics of the study 
population. Correlations were assessed using Kendall’s Tau b. We used the circulating 
folate measures at year 3 to characterize the folic acid and folate status of subjects during 
the first follow-up interval.  In the analysis for the second follow-up interval, we included 
participants whose study folic acid treatment remained unchanged from that in the first 
interval:  those randomized to folic acid who agreed to continue study treatment, those 
allocated folic acid placebo whether or not they agreed to continue study pills, and 100 
participants randomized only to aspirin or placebo (i.e. no randomization to folic 
acid/placebo).  Thus, apart from changes in diet, and non-compliance with the study 
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treatment regimen,  the year 3 blood specimen represented the UFA and mF status during 
the second follow-up interval as well as the first.  
We fit binomial regression models with a log link to describe the associations of 
circulating folate measures at year 3 with the occurrence of adenomas and serrated polyps 
during each of the surveillance intervals.  The endpoints were: ≥1 adenomas; ≥1 advanced 
adenomas; high risk findings; ≥1 serrated lesions.  All analyses were adjusted for age and 
sex, but not for treatment group (which would be reflected in the year 3 plasma 
measurements).  Clinical center did not materially affect the analyses, and was excluded 
from all models. Personal folic acid supplement use during the second follow-up interval 
did not contribute usefully to the models for any of the measured outcomes, either as a 
covariate or as an effect modifier. It was therefore omitted from the analysis, and the same 
model was used for both intervals (i.e. age, sex, mF and UFA). Estimates for mF and UFA 
were mutually adjusted for each other so that the risk ratios reflected the independent 
associations of each analyte.  mF was modeled in quartiles; UFA was modeled in four 
categories, undetectable (set to zero) plus tertiles of the remaining values. We assessed 
patterns of associations with a general test of heterogeneity (Wald test) and tests for trend 
using the linear and quadratic functions of the continuous measurements.  This allowed 
testing of both monotonic trends and the possibility that modest increases in mF or UFA 
levels might be beneficial, while higher levels detrimental. Results are given as relative 
risks of outcome by mF or UFA category. The possibility of effect modification by 
randomized aspirin assignment (dichotomous) or by MTHFR or MTRR polymorphisms was 
assessed using likelihood ratio tests.  All analyses were performed with SAS v9.4.  
 
Results 
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Year 3 plasma measurements and colonoscopy data were available for 924 participants in 
the first interval, 680 of whom completed a further 3-6 years of colonoscopic follow-up 
(Figure 1, Table 1). At enrollment, the mean concentration of mF was 37.7 nmol/L (SD 
22.4); at year 3 this had increased to 46.3 nmol/L (SD 21.7) in the placebo group and 84.8 
nmol/L (SD 29.5) in the folic acid treatment group.  At enrollment, UFA was detected in 
19.3% of participants, with a mean concentration of 4.2 (6.5) nmol/L for the 170 with 
detectable levels.  Just before the 3-year surveillance colonoscopy, detectable UFA was 
found in 23.2% of the placebo group and 73.0% of those in the folic acid group, with mean 
concentrations of 3.4 (8.5) and 21.7 (24.9) nmol/L for those with detectable levels, 
respectively. At year 3, mean plasma mF increased from 48.0 to 97.0 nmol/L within 
increasing categories of UFA (Supplementary Figure 1). The correlation between mF and 
UFA at year 3 was r=0.46 (p<0.0001).  
There were no significant associations between circulating UFA or mF levels and 
overall adenoma risk during either follow-up interval (Table 2).  However, during the 
second follow-up interval, there were indications of an association of mF with increasing 
risk of advanced adenomas and high risk findings (advanced or ≥3 adenomas) (Table 2).  
For high risk findings, there was a linear trend of increasing risk with increasing levels, 
with a 58% increased risk for participants in the upper quartile compared to the lowest 
(Table 2).  There was a weaker, borderline-significant trend for advanced adenomas (25% 
increased risk for upper vs lowest quartile).  During the second interval, UFA showed an 
erratic association with high risk findings, with a borderline significant inverse linear trend 
(p = 0.049).  Analyses without mututal adjustment for mF and UFA showed broadly similar 
findings, though with non-significant trends (Supplementary Table 4). 
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There was no evidence for any differences between men and women in the 
association of mF or UFA with any of these adenoma endpoints (all pinteraction > 0.15, 
Supplementary Table 1). There was also little evidence for a quadratic relationship 
between mF or UFA and these outcomes during early or later follow-up (all p >0.15) (not 
shown). No significant interactions were seen for any outcome between randomized 
aspirin use (dichotomous) and either UFA or mF.  
Associations for serrated pathway lesions differed markedly from those for 
adenomas. During the second surveillance interval, the risk of any serrated lesion was 
significantly inversely associated with plasma mF, with a 39% lower risk for upper vs 
lower quartile participants (Table 3). There was no association with plasma UFA (Table 3).  
 As reported previously for the entire study population (24), there were no 
significant associations between adenoma risk and polymorphisms of MTHFR or MTRR in 
either follow-up interval (Supplementary Table 2).  There were also no indications of 
interactions between plasma levels of mF or UFA and genetic variants in either gene with 
regard to risk of all adenomas (Supplementary Table 2). However, in the corresponding 
analysis of high risk findings, there was an interaction of MTHFR with mF (p = 0.03) during 
the first follow-up interval, with higher mF-associated risk in CC participants than in those 
with the CT/TT genotype. (Supplementary Table 3). In the second interval, there was a 
broadly similar pattern, but the interaction did not reach statistical significance (p=0.08).  
 
Discussion  
In our clinical trial, we previously found that participants randomized to 1mg/day folic acid 
had an increased risk of advanced and multiple adenomas during longer follow-up (2).  In 
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this post hoc analysis, high circulating levels of mF were positively associated with the 
composite high risk endpoint of advanced and/or multiple adenomas during this same 
period, while there was lower risk in the highest category of UFA, with a borderline 
significant trend. These findings suggest that the increased risks seen after folic acid 
supplementation (2) were due to the high mF levels, rather than due to a direct effect of 
UFA itself (Figure 2).  In contrast, our findings for serrated lesions suggested a protective 
effect of higher levels of mF during later follow-up.  
We found an interaction between MTHFR 677C->T and mF levels such that in the 
first follow-up interval there was a particularly elevated risk of high risk findings 
associated with high mF only among individuals homozygous for the CC allele.  This is 
consistent with our finding from the second follow-up interval that mF is associated with 
increased risk, as the enzyme variant associated with the T allele generates 5 methyl-
tetrahydrofolate from 5, 10-methylenetetrahydrofolate less efficiently than the variant 
associated with the C allele.  However, during the second follow-up interval, the interaction 
was less marked. 
Cho et al identified no overall association between circulating UFA and colorectal 
cancer, but with significant heterogeneity by sex, with higher risks among men and lower 
risks among women, with increasing UFA(25). In the second follow-up interval of our 
study, the directions of effects were similar to those seen by Cho et al, but the interactions 
were not statistically significant in our smaller study population. Cho et al also reported a 
significant interaction between UFA and MTHFR C677T, with a colorectal cancer OR of 2.20 
(95% CI 1.22, 3.94) for the highest vs. lowest levels of UFA among those with CT or TT 
genotype. Increasing risks associated with the TT  or CT genotype have been found 
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previously, either as main effects, or with increasing total folate levels (11, 26). We also 
found only slightly and non-significantly higher risk ratios in those with these genotypes at 
highest UFA levels.  
Several laboratory studies indicate that folate or folic acid may enhance 
carcinogenesis in some settings. For example, in mouse models of colorectal cancer, low 
doses of dietary folic acid were protective if given before tumors developed, but promoted 
further tumor growth if given after tumors had emerged (27), and in a rat model of breast 
cancer, folate deficiency was protective (28, 29).  Other in vitro studies have shown that 
folate repletion after deficiency has the potential to lead to carcinogenesis (5). Some argue 
that, because folate antagonists are effective anti-cancer drugs, the rationale for folate 
supplementation to prevent cancer may be flawed; indeed, the use of antifolates in 
leukemia was first prompted by the observation that large doses of folic acid made patients 
with leukemia substantially worse (30).   
Although the inverse association between high risk findings and UFA may be a 
chance finding, there are reasons to speculate that synthetic folic acid might have different 
biological effects than naturally occurring folates (31, 32), some of them potentially 
harmful (33). UFA has been associated with neurological and cognitive effects in 
individuals with lower B12 status (34, 35) and with reduced natural killer cell cytotoxicity 
in some studies in vivo (9, 10), although not in vitro (36).  There are differences in the 
carrier systems through which these natural folates and UFA enter the cell, the points at 
which they enter the folate cycle, and the bioavailability of folates from diet and folic acid 
supplements (31, 37). The assimilation of folic acid into tetrahydrofolate is catalyzed by 
dihydrofolate reductase (DHFR), whose activity varies considerably between individuals 
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and is inhibited by unmetabolized folic acid (38). In addition, UFA may inhibit MTHFR, the 
enzyme that produces methyltetrahydrofolate (39). Thus it is possible that UFA has tissue 
effects that decrease the bioavailability of intracellular mF levels following the 
supplementation.  Further, after administration of radiolabeled folic acid to 10 volunteers, 
40% of the increase in plasma total folate was due to mobilization of endogenous 
(unlabeled) folate rather than conversion of the ingested folic acid (40). The physiological 
differences between UFA and naturally occurring folate species are incompletely 
understood and require further study. The irregular risk ratios seen in the second interval 
of our study may also merit further investigation in future studies, to assess the possibility 
of a threshold effect. 
After folic acid supplementation, 73.0% of our participants had detectable UFA, 
compared with 23.2% of controls; these figures are consistent with the wide range of 
detectable UFA seen in other studies (53-56). UFA has been found in the serum following 
boluses of dietary folic acid as low as 200 mcg in folate-replete women (34), suggesting 
that it should be expected in the serum of individuals taking 1 mg folate/day (57). A variety 
of factors influence the concentration of mF and UFA, including the time since ingestion of 
the supplement (58-60), variability in dietary intake including food fortification and DHFR 
polymorphisms.  We did not control the timing of blood tests relative to pill-taking or meals 
in our study; variable timing would increase the variability of plasma measures and reduce 
our ability to identify associations if any exist. This would be particularly true for UFA, 
which has a short half life (~ one hour) (62) as compared to the more deep folate 
compartments that have previously been detected after chronic supplementation with 
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deuterium labelled folic acid (63). A future study should time blood draws consistently in 
relation to intake of folic acid from foods and supplements. 
Our approach had the advantage of adjustment for serum mF while analyzing the 
effect of UFA and vice versa. By summing the measured concentrations of hm-THF and 5m-
THF, we minimized the measurement error associated with 5m-THF breakdown to hm-
THF in stored samples, (22).  We also used a single blood sample during intervention (near 
the end of the first follow-up interval) to represent UFA or mF levels during two 
observation cycles; this is more reflective of in-trial levels than the pre-supplementation 
samples used in our previous report (17). However, a single measurement is an imperfect 
correlate of long-term exposure, and may cause regression dilution bias that would reduce 
our ability to identify associations(61). A further limitation is that our findings with respect 
to adenoma and especially serrated polyps apply only indirectly to the study of colorectal 
cancer. Finally, in exploring trends in these data, we performed many significance tests, 
with the possibility of type 1 errors, particularly for the quadratic trend tests that were 
conducted; one of 20 tests was statistically significant with P=0.04.  
 
Conclusion 
Our results indicate that the increased risk of advanced/multiple adenomas in later 
follow-up of our trial was likely related to higher levels of plasma mF, and not due to UFA. 
In contrast, findings regarding serrated lesions provide some suggestions of protection 
from mF in the serrated pathway.  While our data do not indicate any significant harm 
associated with UFA itself, the associated high levels of mF seem to be detrimental with 
respect to adenoma risk. The widespread use of folic supplementation and food 
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fortification makes associations between the levels of folate species and disease an 
important avenue for further research. 
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Table 1. Characteristics of trial participants included in serum analyses 
 
 
Enrollment 
Participants who completed 
Interval 1a 
N=924 
Participants who completed 
Interval 2a  
N=680 
Mean (SD) N (%) Mean (SD) N (%) 
Age 57.5 (9.3)  57.6 (9.0)  
Sex:    Male 
            Female 
 587 (63.5) 
337 (36.5) 
 440 (64.7) 
240 (35.3) 
Race/ethnicity:   
            Non Hispanic white 
            Non Hispanic black 
            Hispanic 
            Asian/Pacific Islander 
            Native American 
            Other 
  
784 (84.8) 
54 (5.8) 
56 (6.1) 
22 (2.4) 
4 (0.4) 
4 (0.4) 
  
591 (86.9) 
33 (4.9) 
35 (5.2) 
15 (2.2) 
3 (0.4) 
3 (0.4) 
 
Year 0 
 
N=879 
 
N=649 
mFb mean (SD) nmol/L 37.7 (22.4)  37.7 (22.4)  
Participants with detectable 
UFAc (%) 
 170 (19.3%)  119 (18.3%) 
UFA mean (SD for those with 
detectable levels, nmol/L 
4.2  (6.5)  4.5 (7.3)  
 
Year 3 
 
N= 924 
 
N= 680 
mF mean (SD), nmol/L 
   Folic acid 
   Placebo 
64.1 (32.0) 
84.8 (29.5) 
46.3 (21.7) 
 
 
63.7 (31.7) 
87.0 (27.9) 
46.3 (21.7) 
 
Number of participants with 
detectable UFA (%) 
   Folic acid 
   Placebo 
 428 (46.3%) 
 
313 (73.0%) 
115 (23.2%) 
 314 (46.2%) 
 
230 (79.4%) 
84 (21.5%) 
UFA mean (SD)  for those with 
detectable levels, nmol/L 
   Folic acid 
   Placebo 
16.8 (23.2) 
 
21.7 (24.9) 
3.4 (8.5) 
 16.7 (22.9) 
 
21.4 (24.5) 
3.8 (9.2) 
 
 
 
a Interval 1 is year 0 through the year 3 colonoscopy. Interval 2 began after the year 3 colonoscopy and ended 
6 years later.  
b mF is methylated folate, the sum of measured 5-methyl-THF and 4-α-hydroxy 5-methyl-THF 
c UFA is unmetabolized folic acid. 
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Table 2. Associations of plasma methylated folate (mF) and unmetabolized folic acid (UFA) levels 
with risk of adenomas and serrated lesions 
 
 
Interval 1a Interval 2a 
 
All Adenomasb 
 
N (events) 
RRc (95% confidence 
interval) 
 
N (events) 
RRc (95% confidence 
interval) 
mF  nmol/L 
0-<37.35 218 (86) 1.00 (ref) 170 (62) 1.00 (ref) 
37.35-<60.44 224 (91) 1.02 (0.79, 1.33) 157 (59) 1.00 (0.73, 1.39) 
60.44-<85.50 221 (91) 1.04 (0.78, 1.38) 167 (68) 1.06 (0.75, 1.50) 
≥85.50 224 (87) 1.02 (0.74, 1.42) 162 (60) 1.01 (0.68, 1.50) 
   Pheterogeneity = 0.99d   Pheterogeneity = 0.98d  
   Plinear trend = 0.70   Plinear trend = 0.69 
UFA nmol/L 
0 475 (190) 1.00 (ref) 353 (130) 1.00 (ref) 
>0-<3 163 (69) 1.04 (0.81,1.33) 111 (38) 0.88 (0.62, 1.25) 
3-<20 120 (51) 1.00 (0.74,1.35) 91 (45) 1.31 (0.95, 1.82) 
≥20 129 (45) 0.83 (0.58,1.18) 101 (36) 0.96 (0.64, 1.43) 
   Pheterogeneity = 0.64d    Pheterogeneity = 0.14d  
   Plinear trend = 0.13   Plinear trend = 0.81 
 
High Risk Findingse 
 
 
 
mF nmol/L 
0-<37.35 214 (25) 1.00 (ref) 170 (15) 1.00 (ref) 
37.35-<60.44 222 (35) 1.35 (0.87,2.11) 157 (19) 1.13 (0.71, 2.36) 
60.44-<85.50 216 (26) 1.02 (0.61,1.71) 167 (25) 1.56 (0.84, 2.90) 
≥85.50 223 (32) 1.32 (0.77,2.24) 162 (21) 1.58 (0.80, 3.09) 
   Pheterogeneity = 0.38d    Pheterogeneity = 0.52d  
   Plinear trend = 0.96   Plinear trend = 0.009 
UFA nmol/L 
0 467 (63) 1 353 (38) 1 
>0-<3 160 (21) 0.94 (0.60,1.46) 111 (16) 1.11 (0.65, 1.89) 
3-<20 119 (20) 1.17 (0.73,1.88) 91 (18) 1.46 (0.86, 2.50) 
≥20 129 (14) 0.73 (0.41,1.29) 101 (8) 0.59 (0.28, 1.24) 
   Pheterogeneity =0.45d    Pheterogeneity = 0.10d  
   Plinear trend = 0.46   Plinear trend = 0.049 
 
Advanced Adenomaf 
   
mF nmol/L 
 19 
0-<37.35 214 (19) 1 166 (13) 1 
37.35-<60.44 221 (24) 1.28 (0.78,2.10) 150 (14) 1.11  (0.59, 2.07) 
60.44-<85.50 214 (18) 1.09 (0.62, 1.91) 162 (17) 1.18 (0.61, 2.28) 
≥85.50 222 (23) 1.56 (0.88,2.77) 158 (15) 1.25 (0.61, 2.55) 
   Pheterogeneity = 0.39d    Pheterogeneity =0.94d  
   Plinear trend = 0.73   Plinear trend = 0.051 
UFA nmol/L 
0 466 (48) 1 341 (28) 1 
>0-<3 159 (16) 0.91 (0.56,1.47) 108 (13) 1.35 (0.76, 2.38) 
3-<20 119 (11) 0.80 (0.44,1.41) 89 (13) 1.60 (0.88, 2.94) 
≥20 127 (9) 0.60 (0.29, 1.09) 98 (5) 0.55 (0.23, 1.32) 
   Pheterogeneity = 0.40d    Pheterogeneity = 0.07d  
   Plinear trend = 0.24   Plinear trend = 0.07 
 
Serrated Lesionsg 
    
mF  nmol/L     
0-<37.35 223 (74) 1 167 (52) 1 
37.35-<60.44 222 (47) 0.63 (0.44 0.90) 155 (43) 0.88 (0.60, 1.28) 
60.44-<85.50 219 (66) 0.87 (0.61, 1.25) 163 (44) 0.90 (0.60, 1.37) 
≥85.50 226 (66) 0.85 (0.57, 1.26) 158 (28) 0.61 (0.36, 1.23) 
   Pheterogeneity = 0.09d   Pheterogeneity = 0.30d 
   Plinear trend = 0.66   Plinear trend = 0.03 
UFA nmol/L     
0 478 (134) 1.00 (ref) 346 (98) 1.00 (ref) 
>0-<3 162 (45) 1.03 (0.72, 1.45) 112 (34) 1.18 (0.81 1.73) 
3-<20 121 (38) 1.12 (0.76, 1.66) 87 (17) 0.78 (0.46, 1.35) 
≥20 129 (36) 0.98 (0.64, 1.50) 98 (18) 0.82 (0.47, 1.45) 
   Pheterogeneity =0.93d   Pheterogeneity = 0.43d 
   Plinear trend = 0.66   Plinear trend = 0.91 
a Interval 1 is year 0 through the year 3 colonoscopy. Interval 2 began after the year 3 colonoscopy and ended 
6 years later.  
b Conventional adenomas: tubulovillous, villous or tubular adenomas (i.e. non serrated) 
c Risk ratios are estimated for each quartile of mF [or UFA], with respect to the first quartile as referent, in the 
following model: colonoscopy findings = age + sex + quartiles of mF [or UFA] + continuous UFA [or mF] 
d Wald test 
e High risk findings: 3 or more adenomas or advanced adenoma  
f Advanced adenoma: tubulovillous or villous adenomas, or adenomas that were large (≥1cm) or had invasive 
cancer or high grade dysplasia 
g Serrated lesions: hyperplastic polyps, sessile serrated adenomas/polyps, and traditional serrated adenomas  
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Figure 1. Design of the trial and participants studied in this analysis (adapted from Cole et 
al, 2007 (2)) 
 
 
 
 
 
 
	
1409	individuals	entered	run-in	
388	exclusions	
1021	randomized	in	folic	acid	study	(+/-	aspirin)	
505	randomized	to	receive	
placebo	+/-	aspirin	
516	randomized	to	receive	1	
mg/	day	folic	acid	+/-	aspirin	
486	completed	first	follow-
up	exam	(13	lost	to	follow-
up;	6	died);	of	these,	411	
had	y3	folate	measured	
501	completed	first	follow-up	
exam	(12	lost	to	follow-up;	3	
died);	of	these,	429	had	y3	
folate	measured		
391	with	y3	folate	measure	
consented	to	pill-taking	or	
extended	follow-up	without	
pill-taking	
331	with	y3	folate	measure	
consented	to	continued	pill-
taking		
329	with	y3	folate	measure	
completed	second	follow-up	
exam	up	to	9	years	from	
enrollment	
290	with	y3	folate	measure	
completed	second	follow-up	
exam	up	to	9	years	from	
enrollment	
100	randomized	to	aspirin	
or	placebo,	but	no	folic	acid	
97	completed	first	follow-up	
exam	(2	lost	to	follow-up;	1	
died);	of	these,	84	had	y3	
folate	measured	
72	with	y3	folate	measure	
consented	to	pill-taking	or	
extended	follow-up	without	
pill-taking	
61	with	y3	folate	measure	
completed	second	follow-up	
exam	up	to	9	years	from	
enrollment	
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Figure 2. Possible causal pathways under investigation 
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